These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 22003405)
1. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. Dayyeh BK; Gupta N; Sherman KE; de Bakker PI; Chung RT; PLoS One; 2011; 6(10):e25753. PubMed ID: 22003405 [TBL] [Abstract][Full Text] [Related]
2. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315 [TBL] [Abstract][Full Text] [Related]
3. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. Fernández-Rodríguez A; Rallón N; Berenguer J; Jiménez-Sousa MA; Cosín J; Guzmán-Fulgencio M; Restrepo C; Lopez JC; García-Álvarez M; Miralles P; Soriano V; Benito JM; Resino S AIDS; 2013 Jan; 27(2):163-73. PubMed ID: 23135173 [TBL] [Abstract][Full Text] [Related]
4. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235 [TBL] [Abstract][Full Text] [Related]
5. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939 [TBL] [Abstract][Full Text] [Related]
6. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV. Matas M; Picornell A; Cifuentes C; Payeras A; Homar F; González-Candelas F; López-Labrador FX; Moya A; Ramon C; Castro JA Int Microbiol; 2014 Mar; 17(1):11-20. PubMed ID: 25296442 [TBL] [Abstract][Full Text] [Related]
7. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709 [TBL] [Abstract][Full Text] [Related]
8. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184 [TBL] [Abstract][Full Text] [Related]
9. Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection. Keane C; O'Shea D; Reiberger T; Peck-Radosavljevic M; Farrell G; Bergin C; Gardiner CM PLoS One; 2013; 8(6):e66831. PubMed ID: 23826153 [TBL] [Abstract][Full Text] [Related]
10. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients. Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G; New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009 [TBL] [Abstract][Full Text] [Related]
12. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. Amorosa VK; Luetkemeyer A; Kang M; Johnson VA; Umbleja T; Haas DW; Yesmin S; Bardin MC; Chung RT; Alston-Smith B; Tebas P; Peters MG HIV Clin Trials; 2013; 14(6):274-83. PubMed ID: 24334180 [TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin. Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160 [TBL] [Abstract][Full Text] [Related]
14. IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients. Zeremski M; Dimova RB; Makeyeva J; Sipley JD; Jacobson IM; Rennert H; Talal AH J Acquir Immune Defic Syndr; 2013 May; 63(1):9-16. PubMed ID: 23274935 [TBL] [Abstract][Full Text] [Related]
15. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823 [TBL] [Abstract][Full Text] [Related]
16. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692 [TBL] [Abstract][Full Text] [Related]
17. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes. Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679 [TBL] [Abstract][Full Text] [Related]
18. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925 [TBL] [Abstract][Full Text] [Related]
19. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. Vispo E; Rallon NI; Labarga P; Barreiro P; Benito JM; Soriano V J Clin Virol; 2012 Sep; 55(1):58-61. PubMed ID: 22727259 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]